Cite
Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer.
MLA
Shi, Xiao, et al. “Combined Transcriptome and Proteome Analysis Reveals MSN and ARFIP2 as Biomarkers for Trastuzumab Resistance of Breast Cancer.” Breast Cancer Research & Treatment, vol. 207, no. 1, Aug. 2024, pp. 187–201. EBSCOhost, https://doi.org/10.1007/s10549-024-07355-1.
APA
Shi, X., Sheng, Y., Fei, H., Wei, B., Zhang, Z., Xia, X., Mao, C., & Si, X. (2024). Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer. Breast Cancer Research & Treatment, 207(1), 187–201. https://doi.org/10.1007/s10549-024-07355-1
Chicago
Shi, Xiao, Yuan Sheng, Haoran Fei, Bangbang Wei, Zhenyu Zhang, Xinyu Xia, Changfei Mao, and Xinxin Si. 2024. “Combined Transcriptome and Proteome Analysis Reveals MSN and ARFIP2 as Biomarkers for Trastuzumab Resistance of Breast Cancer.” Breast Cancer Research & Treatment 207 (1): 187–201. doi:10.1007/s10549-024-07355-1.